Skip to main content
Smart Investors Daily
BB

NASDAQ · BBOT

BridgeBio Oncology Therapeutics Inc.

Healthcare · Biotechnology

$2.14

Down-$0.16 (-7.48%)

Updated Nov 17, 2026, 1:44 AM

SID Score

3.3/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.03B
P/E ratio
-2.62
Dividend yield
0.00%
52-week range
$1.98 – $14.87
Volume
677.6K
Avg. volume
237.22K

Price performance · BBOT

BBOT price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Nov 13, 2026

BBOT closed at $2.14 after 20 trading sessions, down 24.91% for the selected period.

Last close
$2.14
Period change
-24.91%
Period low
$2.04
Period high
$2.85
Daily close
View OHLC price history
BBOT OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 13, 2026$2.37$2.37$2.11$2.14677.6K
Nov 12, 2026$2.50$2.68$2.00$2.35779.14K
Nov 11, 2026$2.33$2.65$2.25$2.561.42M
Nov 10, 2026$2.29$2.34$2.185$2.20486.87K
Nov 9, 2026$2.09$2.34$2.07$2.30780.84K
Nov 6, 2026$2.19$2.25$1.98$2.04687.05K
Nov 5, 2026$2.30$2.30$2.07$2.17699.09K
Nov 4, 2026$2.33$2.39$2.22$2.30451.53K
Nov 3, 2026$2.30$2.4025$2.29$2.32621.27K
Nov 2, 2026$2.64$2.64$2.295$2.31579.58K
Oct 30, 2026$2.70$2.74$2.605$2.62314.79K
Oct 29, 2026$2.81$2.9475$2.69$2.70357.04K
Oct 28, 2026$2.67$2.855$2.61$2.80482.22K
Oct 27, 2026$2.65$2.725$2.51$2.691.76M
Oct 26, 2026$2.66$2.68$2.61$2.64483.08K
Oct 23, 2026$2.83$2.83$2.60$2.66737.35K
Oct 22, 2026$2.66$2.85$2.66$2.85661.9K
Oct 21, 2026$2.71$2.855$2.66$2.68942.24K
Oct 20, 2026$2.85$2.98$2.70$2.72660.93K
Oct 19, 2026$2.84$2.90$2.79$2.85695.64K

Latest BBOT news

The latest Smart Investors Daily articles mentioning BBOT.

BBOT research

Overview

Company profile and research snapshot.

Company profile

BridgeBio Oncology Therapeutics Inc, formerly BridgeBio Oncology Therapeutics is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$23.20
Implied upside
—
Analysts
—
BBOT recent ratings
DateFirmRatingTarget
Nov 11, 2026WedbushOutperform—
Nov 11, 2026Piper SandlerOverweight—
Oct 21, 2026Morgan StanleyOverweight—
Oct 20, 2026OppenheimerOutperform—
Sep 11, 2026JP MorganOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 10, 2026

BBOT Reports Third Quarter 2026 Financial Results and Update on Corporate Progress

BBO-8520 plus pembrolizumab demonstrated a 75% ORR at 500 mg QD and 53% ORR across dose levels in 2L+ KRASG12C inhibitor-experienced NSCLC patientsBBO-11818 and BBO-10203 combination cohorts enrolling in KRAS-mutant colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC); BBO-11818 and BBO-10203 monotherapy data update expected in the fourth quarter of 2026Cash runway expected to fund operations into 2029 SOUTH SAN FRANCISCO, Calif., Nov. 10, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncolo

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.